Letter in support of Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

SUMMARY: Letter from Consumer Reports to House Judiciary Committee in support of HR 5133, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2019. This bill clarifies and strengthens the enforcement authority of the Federal Trade Commission against “product hopping,” the practice by a brand-name prescription drug maker of making a minor, inconsequential change in a drug in order to artificially prolong its patent-protected monopoly profits, while at the same time discontinuing the just-as-effective version that generics are on the verge of replicating at a lower price, thus to delay and frustrate the availability of more affordable generic prescription drugs.